About Santaris Pharma
Santaris Pharma is a Healthcare company based in Copenhagen (Denmark) founded in 2003 by Peter Sondermann, and was acquired by Roche in August 2014. RNA-targeted therapies for infectious and metabolic diseases are developed. Santaris Pharma has raised $104.3 million across 5 funding rounds from investors including Pfizer, Roche and European Union. Its chief executive, as recorded, is Peter Sondermann. Its focus areas include Life Sciences, Gene Therapy, RNA and siRNA.
Company details
Santaris Pharma was founded in 2003 in Copenhagen, Denmark, by Peter Sondermann, who serves as CEO. RNA-targeted therapeutics are developed using the proprietary Locked Nucleic Acid (LNA) platform and a drug discovery system. Focus is placed on infectious diseases and cardiometabolic disorders, with operations centered in biotechnology. The lead candidate, miravirsen (SPC3649), is advanced as a modified RNA molecule for hepatitis C treatment.
- Headquarters Copenhagen, Denmark
- Founders Peter Sondermann
- Stage Acquired
- SectorsHealthcare
- Website santaris.com
- Acquired by Roche (Aug 2014)
Funding Insights of Santaris Pharma
Santaris Pharma has successfully raised a total of $104.3M across 5 strategic funding rounds. The most recent funding activity was a Series C round of $12 million completed in June 2012. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $104.3M
- Total Rounds 5
- Last Round Series C — $12M
- First Round $48.3M
(Mar 2006)
- Investors Count 14
All 5 funding rounds of Santaris Pharma with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2012 | $12M | Series C | – | Forbion, Seventure Partners | – |
| Jan 2011 | $14M | Series C | – | Pfizer | – |
| May 2008 | $9M | Grant | – | – | |
| Dec 2007 | $30M | Series B | – | Gilde Healthcare, BankInvest | – |
| Mar 2006 | $48.3M | Series B | – | Global Life Science Ventures, Vaekstfonden | – |
15 investors in total: 15 institutional.
Investors in Santaris Pharma
Santaris Pharma has secured backing from 15 investors, including venture fund and institutional investors. Prominent investors backing the company include Pfizer, Roche and European Union.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital firm focused on lifescience and healthcare sectors | forbion.com | Naarden, Netherlands | ||
Tech & Life Sciences focused stage agnostic VC firm investing in Europe, Asia & the US | seventure.fr | Paris, France | ||
Investments are made by Sunstone in early-stage European companies. | sunstone.eu | Copenhagen, Denmark | ||
Private equity and venture captial firm focused on healthcare sectors | gildehealthcare.com | Cambridge, United States | ||
Early & late stage life sciences focused VC firm funding companies in the US and Europe | global-life-science-ventures.com | Munich, Germany | ||
Private equity and venture capital fund focused on the healthcare sector | novoholdings.dk | Hellerup, Denmark | ||
Early-stage centric Tech-focused VC Firm funding companies in the US | innovationcapital.com | Wilmington, United States | ||
Provision of financing, loans, equity, and insurance for Danish export and investment activities. | vf.dk | |||
Private equity investments are directed toward ESG-focused companies. | majinvest.com | Copenhagen, Denmark | ||
| innkap.se |
Investor details for Santaris Pharma
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Santaris Pharma
1 people are tracked at Santaris Pharma (1 in leadership).
| Name | Role | Group |
|---|---|---|
Peter Sondermann | Founder & CEO | Leadership |
Complete people profiles for Santaris Pharma
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Santaris Pharma
4 dated milestones of Santaris Pharma across 11 years, from founding to its latest funding, stage changes and deals.
- Founded Santaris Pharma is founded.
- Funding First funding round of $48.3M.
- Funding Latest funding round, Series C, of $12.0M.
- Exit Acquired by Roche.
Web traffic of Santaris Pharma
Websites that share an audience with Santaris Pharma (santaris.com).
Websites whose visitors overlap most with Santaris Pharma. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| exiqon.com | 100% | View details | |||
| virxsys.com | 99% | View details | |||
| asuragen.com | 99% | 8.4K | #2,708,489 | View details | |
atugen.com | atugen.com | 99% | #14,513,602 | – | |
| ribotask.com | 99% | View details | |||
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 17 similar websites and full traffic analytics for Santaris Pharma
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 17 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Santaris Pharma
Complete news archive for Santaris Pharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Santaris Pharma
Santaris Pharma was founded in 2003 and raised its 1st funding round 3 years after it was founded.
Santaris Pharma is headquartered in Copenhagen, Denmark.
Peter Sondermann is the CEO of Santaris Pharma, as recorded in our data. They have also founded this company.
Santaris Pharma is a funded company, having raised a total of $104.3M across 5 funding rounds to date. The company's 1st funding round was a Series B of $48.3M, raised on Mar 2006.
Santaris Pharma was founded in 2003 in Copenhagen, Denmark, by Peter Sondermann, who serves as CEO. RNA-targeted therapeutics are developed using the proprietary Locked Nucleic Acid (LNA) platform and a drug discovery system. Focus is placed on infectious diseases and cardiometabolic disorders, with operations centered in biotechnology. The lead candidate, miravirsen (SPC3649), is advanced as a modified RNA molecule for hepatitis C treatment.
Santaris Pharma has 15 investors. Key investors include Pfizer, Roche, European Union, Forbion, and Seventure Partners.
Yes. Santaris Pharma was acquired by Roche in August 2014.